<DOC>
	<DOCNO>NCT01533441</DOCNO>
	<brief_summary>The objective SAFE K study demonstrate patient treat antagonist vitamin K ( VKA ) , daily intake vitamin K2 ( 75 micrograms/day ) naturally produce ferment use ferment dairy product , upset balance anticoagulant treatment.Fifty-two patient choose receive either verum placebo four month 4-month run-in period.In addition , study evaluate regular consumption vitamin K2 reduce need change dose anticoagulation treatment improve marker bone mineralisation .</brief_summary>
	<brief_title>Vitamin K2 Intervention Patients With Vitamin K Antagonists</brief_title>
	<detailed_description>Randomisation study subject do two randomisation list depend whether dose VKA high low . Randomisation balance stratified depending average dose VKA inclusion order arm would number patient receive dose low use anticoagulant treatment . The level vitamin K intake determine study visit use dietary questionnaire .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 2</mesh_term>
	<mesh_term>Vitamin MK 7</mesh_term>
	<criteria>treated anticoagulant INR range 23 TTR ( time therapeutic range ) equal high 56 % 4 month inclusion consumption significant amount product conatining vitamin K regular consumption dietary supplement susceptible contain vitamin K milk intolerant refuse daily consumption dairy product previous insufficient earlier therapeutic VKA followup cardiac , renal severe respiratory insufficiency , diseases interfere fat absorption , significant abnormality safety parameter , clinically significant thrombotic hemorrhagic event</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>anticoagulant therapy</keyword>
	<keyword>INR</keyword>
	<keyword>vitamin K2</keyword>
	<keyword>vitamin K antagonist</keyword>
</DOC>